U.S. health authorities said Thursday that 16- and 17-year-olds should get a booster dose of Pfizer's COVID-19 vaccine once they're six months past their last shot.
The U.S. and many other nations already were urging adults to get booster shots to pump up immunity that can wane months after vaccination, calls that intensified with the discovery of the worrisome new omicron variant.
On Thursday, the Food and Drug Administration gave emergency authorization for 16- and 17-year-olds to get a third dose of the vaccine made by Pfizer and its partner BioNTech. And hours later, the Centers for Disease Control and Prevention lifted the last barrier — saying those teens should get their booster as soon as it's time.
CDC Director Rochelle Walensky told The Associated Press the boosters are important considering that protection against infection wanes over time and “we’re facing a variant that has the potential to require more immunity to be protected.”
“Vaccination and getting a booster when eligible, along with other preventive measures like masking and avoiding large crowds and poorly ventilated spaces, remain our most effective methods for fighting COVID-19,” Dr. Janet Woodcock, acting FDA commissioner, said in a statement.
The Pfizer vaccine is the only option in the U.S. for anyone younger than 18, either for initial vaccination or for use as a booster. It’s not yet clear if or when teens younger than 16 might need a third Pfizer dose.
Vaccinations for children as young as 5 just began last month, using special low-dose Pfizer shots. By this week, about 5 million 5- to 11-year-olds had gotten a first dose.
The extra-contagious delta variant is causing nearly all COVID-19 infections in the U.S., and in much of the world. It’s not yet clear how vaccines will hold up against the new and markedly different omicron mutant. But there’s strong evidence that boosters offer a jump in protection against delta-caused infections, currently the biggest threat.
Complicating the decision to extend boosters to 16- and 17-year-olds is that the Pfizer shot -- and a similar vaccine made by Moderna -- have been linked to a rare side effect. Called myocarditis, it’s a type of heart inflammation seen mostly in younger men and teen boys.
The FDA said rising COVID-19 cases in the U.S. mean the benefits of boosters greatly outweighed the potential risk from the rare side effect, especially as the coronavirus itself can cause more serious heart inflammation.
Health officials in Israel, which already gives boosters to teens, have said the side effect continues to be rare with third doses.
A U.S. study this week offered additional reassurance. Researchers from children’s hospitals around the country checked medical records and found the rare side effect usually is mild and people recover quickly. The research was published Monday in the journal Circulation.
___
Associated Press reporter Matthew Perrone contributed to this report.
Bioscience and genetic engineering company, Colossal, raised $60 million in a Series A funding round. Colossal is focused on developing new technologies and genetic tools to restore extinct species, and protect critically endangered species. One of the startup's long-term goals is to resurrect the woolly mammoth, and return it back to the arctic. Colossal also says it is developing technology that expands beyond animals, and has the potential to advance human health. Ben Lamm, co-founder and CEO of Colossal, joins Cheddar News' Closing Bell to discuss.
Residents were cleaning their homes Thursday after a 7.4-magnitude earthquake struck off the coast of Fukushima in northern Japan, smashing furniture, knocking out power and killing four people.
A New Zealand couple who believed they had dug up the world’s largest potato had their dreams turned to mash after Guinness World Records wrote to say that scientific testing had found it wasn’t, in fact, a potato after all.
Two years into the pandemic, many of us have regained a sense of normalcy. However, those in the healthcare industry are still confronting the virus every day, dealing with the physical, mental and psychological stress of the ongoing pandemic. Ben Mirtes, CFO of Ingenovis Health and Lydia Mobley, a travel nurse with Faststaff, who has spent the last two years going from hotspot to hotspot, joined Cheddar’s Opening Bell to reflect on their experiences in healthcare, and discuss why they are optimistic about a path forward.
Catching you up on what you Need to Know on March 16, 2022, with updates on Ukraine and Russia, a container ship gets stuck in the Chesapeake Bay, Disney employees stage a walkout over the "Don't Say Gay" law in Florida, and NASA completes its first spacewalk of 2022.
Food technology startup Tender Food raised $12 million in a seed round led by Chris Sacca's Lowercarbon Capital. Tender says it specializes in creating alternative meats with an authentic texture and is on a mission to make alternative meats so delicious, nutritious, and affordable, that eating meat from animals will no longer make sense. Christophe Chantre, co-founder & CEO of Tender Food, joins Cheddar News' Closing Bell to discuss.
Ryan Shearman, chief alchemist and co-founder at Aether, and Henry Elkus, founder of Helena, join Cheddar News to talk about the completion of an $18 million Series A funding round led by Helena.
As the Russia-Ukraine conflict continues to grow, so do concerns over the impact it could have on the international space community, and more specifically, the International Space Station. Those concerns come after Dmitry Rogozin, the director of Russia's state space agency, posted several tweets over the last few weeks in which he threatened to 'destroy Russia's cooperation on the ISS.' Olympia LePoint, rocket scientist and author of 'Answers Unleashed II: The Science of Attracting What You Want,' joined Cheddar News' Closing Bell to discuss.
